Marion Dajon, Kristina Iribarren, I. Cremer
Jan 9, 2015
Citations
0
Influential Citations
31
Citations
Journal
OncoImmunology
Abstract
Toll-like receptor 7 (TLR7) agonists are under investigation for their ability to enhance antitumor immune responses. However, these agonists can also stimulate TLR7-expressing tumor cells. High TLR7 expression in the primary tumor confers poor clinical outcome and resistance to chemotherapy in lung cancer patients. This protumorigenic effect of TLR7 has been validated in murine models of lung carcinoma.